Elsevier Science, Inc.

SHERPA: Unknown

People

  1. Norton
    Norton
  2. Motzer
    Motzer
  3. Rosa
    Rosa
  4. Sepkowitz
    Sepkowitz
  5. Tap
    Tap
  6. Kingham
    Kingham
  7. Robson
    Robson
  8. Hudis
    Hudis
  9. Janjigian
    Janjigian
  10. Morris
    Morris

Groups

  1. Department of Medicine (74)
  2. Solid Tumor Oncology Division (52)
  3. Surgery (23)
  4. Population Sciences Research Program (21)
  5. GSK Faculty (16)
  6. Breast Medicine Service (14)
  7. Genitourinary Oncology Service (14)
  8. Hematologic Malignancies, Division of (14)
  9. Center for Hematologic Malignancies (13)
  10. Survivorship Research (12)
Search Within
  1. "Lancet"
Formats
  1. Journal Article (142)
  2. Review (9)
  3. Correspondence (7)
  4. Editorial (6)
  5. Meeting Abstract (2)
Groups
  1. Department of Medicine (74)
  2. Solid Tumor Oncology Division (52)
  3. Surgery (23)
  4. Population Sciences Research Program (21)
  5. GSK Faculty (16)
  6. Breast Medicine Service (14)

More Groups

People
  1. Larry Norton (7)
  2. Robert Motzer (6)
  3. Kent Sepkowitz (5)
  4. Robert Wittes (5)
  5. Thomas Hakes (5)
  6. William Rosa (5)

More People

Years
  1. 2025 (6)
  2. 2024 (12)
  3. 2023 (14)
  4. 2022 (4)
  5. 2021 (8)
  6. 2020 (5)

More Years

Publications
  1. Lancet (166)

Results (166)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Pexidartinib versus placebo for advanced tenosynovial giant cell tumour (ENLIVEN): A randomised phase 3 trial
    Journal Article

    Tap, W. D.; Gelderblom, H.; Palmerini, E.; Desai, J.; Bauer, S.; Blay, J. Y.; Alcindor, T.; Ganjoo, K.; Martín-Broto, J.; Ryan, C. W.; more...
    Lancet (2019)

    Fulltext@MSK | Save
  • Atezolizumab plus bevacizumab versus sunitinib in patients with previously untreated metastatic renal cell carcinoma (IMmotion151): A multicentre, open-label, phase 3, randomised controlled trial
    Journal Article

    Rini, B. I.; Powles, T.; Atkins, M. B.; Escudier, B.; McDermott, D. F.; Suarez, C.; Bracarda, S.; Stadler, W. M.; Donskov, F.; Lee, J. L.; more...
    Lancet (2019)

    Fulltext@MSK | Save
  • Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: A patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials
    Journal Article

    Early Breast Cancer Trialists’ Collaborative Group (EBCTCG)
    Lancet (2019)

    Fulltext@MSK | Save
  • Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): A global, double-blind, randomised, phase 3 trial
    Journal Article

    Horwitz, S.; O'Connor, O. A.; Pro, B.; Illidge, T.; Fanale, M.; Advani, R.; Bartlett, N. L.; Christensen, J. H.; Morschhauser, F.; Domingo-Domenech, E.; more...
    Lancet (2019)

    Fulltext@MSK | Save
  • Discrepancies in guidelines for acute respiratory distress syndrome
    Journal Article

    Rochwerg, B.; Meduri, U.; Pastores, S.; Annane, D.
    Lancet (2018)

    Fulltext@MSK | Save
  • Forecasting life expectancy, years of life lost, and all-cause and cause-specific mortality for 250 causes of death: Reference and alternative scenarios for 2016-40 for 195 countries and territories
    Journal Article

    Foreman, K. J.; Marquez, N.; Dolgert, A.; Fukutaki, K.; Fullman, N.; McGaughey, M.; Pletcher, M. A.; Smith, A. E.; Tang, K.; Yuan, C. W.; more...
    Lancet (2018)

    Fulltext@MSK | Save
  • Inactivated varicella zoster vaccine in autologous haemopoietic stem-cell transplant recipients: An international, multicentre, randomised, double-blind, placebo-controlled trial
    Journal Article

    Winston, D. J.; Mullane, K. M.; Cornely, O. A.; Boeckh, M. J.; Brown, J. W.; Pergam, S. A.; Trociukas, I.; Žák, P.; Craig, M. D.; Papanicolaou, G. A.; more...
    Lancet (2018)

    Fulltext@MSK | Save
  • International validation of the consensus Immunoscore for the classification of colon cancer: A prognostic and accuracy study
    Journal Article

    Pagès, F.; Mlecnik, B.; Marliot, F.; Bindea, G.; Ou, F. S.; Bifulco, C.; Lugli, A.; Zlobec, I.; Rau, T. T.; Berger, M. D.; more...
    Lancet (2018)

    Fulltext@MSK | Save
  • Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial
    Journal Article

    Coleman, R. L.; Oza, A. M.; Lorusso, D.; Aghajanian, C.; Oaknin, A.; Dean, A.; Colombo, N.; Weberpals, J. I.; Clamp, A.; Scambia, G.; more...
    Lancet (2017)

    Fulltext@MSK | Save
  • Bevacizumab for advanced cervical cancer: Final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240)
    Journal Article

    Tewari, K. S.; Sill, M. W.; Penson, R. T.; Huang, H.; Ramondetta, L. M.; Landrum, L. M.; Oaknin, A.; Reid, T. J.; Leitao, M. M.; Michael, H. E.; more...
    Lancet (2017)

    Fulltext@MSK | Save